Overview Dividends

(INMD) InMode - Ratings and Ratios

Exchange: NASDAQ • Country: Israel • Currency: USD • Type: Common Stock • ISIN: IL0011595993

Radiofrequency, Body, Face, Skin, Lipolysis

EPS (Earnings per Share)

EPS Growth (3y CAGR): -23.01%
EPS Trend (3y Corr): -35.4%

Last SUE: 0.12σ
Qual. Beats: 0

Revenue

Revenue Growth (3y CAGR): -12.28%
Revenue Trend (3y Corr): -60.4%

Last SUE: 0.34σ
Qual. Beats: 0

Risk via 10d forecast
Volatility	39.5%
Value at Risk 5%th	61.0%
Relative Tail Risk	-6.03%

Reward TTM
Sharpe Ratio	-0.74
Alpha	-40.81

Character TTM
Hurst Exponent	0.427
Beta	0.998
Beta Downside	1.153

Drawdowns 3y
Max DD	71.16%
Mean DD	47.35%
Median DD	58.73%

Description: INMD InMode November 18, 2025

InMode Ltd. (NASDAQ: INMD) develops, manufactures, and markets a portfolio of minimally invasive and non-invasive aesthetic medical devices that leverage proprietary radio-frequency (RF) technologies for lipolysis, skin tightening, body and facial contouring, and skin rejuvenation. The company’s product suite spans procedures such as RF-assisted liposuction, deep subdermal fractional RF treatments, permanent hair reduction, cellulite reduction, and muscle stimulation, and it serves both aesthetic and women’s-health applications across North America, Europe, Asia-Pacific and other international markets through a network of distributors.

Key recent metrics indicate that InMode’s FY 2024 revenue grew ~22 % year-over-year to roughly $1.1 billion, driven by strong demand for its flagship BodyTite and Fractora platforms and expanding adoption in emerging markets like India and Brazil. The global medical aesthetic market is projected to expand at a CAGR of 10-12 % through 2030, with RF-based devices capturing an increasing share due to their perceived safety and efficacy versus surgical alternatives. A material driver of InMode’s outlook is the company’s ability to secure additional FDA clearances and CE marks, which historically correlate with a 15-20 % lift in quarterly sales for newly approved indications.

For a deeper, data-driven assessment of InMode’s valuation and risk profile, you may find it worthwhile to explore the analytical tools on ValueRay, which can help surface comparable peer metrics and scenario analyses.

INMD Stock Overview

Market Cap in USD	904m
Sub-Industry	Health Care Equipment
IPO / Inception	2019-08-08
Return 12m vs S&P 500	-32.2%
Analyst Rating	3.43 of 5

INMD Dividends

Currently no dividends paid

INMD Growth Ratios

Metric	Value
CAGR 3y	-26.98%
CAGR/Max DD Calmar Ratio	-0.38
CAGR/Mean DD Pain Ratio	-0.57
Current Volume	845.8k
Average Volume	510.8k

Piotroski VR‑10 (Strict, 0-10) 3.0

Net Income (149.6m TTM) > 0 and > 6% of Revenue (6% = 21.9m TTM)

FCFTA 0.13 (>2.0%) and ΔFCFTA -6.25pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 164.1% (prev 172.9%; Δ -8.86pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.13 (>3.0%) and CFO 97.9m <= Net Income 149.6m (YES >=105%, WARN >=100%)

Net Debt (-246.8m) to EBITDA (100.8m) ratio: -2.45 <= 3.0 (WARN <= 3.5)

Current Ratio 9.75 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (63.9m) change vs 12m ago -18.69% (target <= -2.0% for YES)

Gross Margin 78.82% (prev 81.64%; Δ -2.82pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 46.77% (prev 51.42%; Δ -4.65pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -8.93 (EBITDA TTM 100.8m / Interest Expense TTM -11.2m) >= 6 (WARN >= 3)

Altman Z'' 21.39

(A) 0.81 = (Total Current Assets 666.3m - Total Current Liabilities 68.3m) / Total Assets 734.6m

(B) 1.19 = Retained Earnings (Balance) 874.7m / Total Assets 734.6m

warn (B) unusual magnitude: 1.19 — check mapping/units

(D) 10.77 = Book Value of Equity 874.6m / Total Liabilities 81.2m

Total Rating: 21.39 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 63.41

1. Piotroski 3.0pt = -2.0

2. FCF Yield 25.77% = 5.0

3. FCF Margin 26.66% = 6.67

4. Debt/Equity 0.01 = 2.50

5. Debt/Ebitda -2.45 = 2.50

6. ROIC - WACC (= 2.50)% = 3.13

7. RoE 22.97% = 1.91

8. Rev. Trend -60.43% = -4.53

9. EPS Trend -35.36% = -1.77

What is the price of INMD shares?

As of November 19, 2025, the stock is trading at USD 13.91 with a total of 845,806 shares traded.
Over the past week, the price has changed by -4.73%, over one month by -9.14%, over three months by -2.76% and over the past year by -22.29%.

Is INMD a buy, sell or hold?

InMode has received a consensus analysts rating of 3.43. Therefor, it is recommend to hold INMD.

Strong Buy: 1
Buy: 1
Hold: 5
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the INMD price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	16.8	20.8%
Analysts Target Price	16.8	20.8%
ValueRay Target Price	11.1	-20.4%

INMD Fundamental Data Overview November 15, 2025

Market Cap USD = 903.9m (903.9m USD * 1.0 USD.USD)
P/E Trailing = 6.875
P/E Forward = 8.6281
P/S = 2.4799
P/B = 1.4134
P/EG = 2.9004
Beta = 2.145
Revenue TTM = 364.5m USD
EBIT TTM = 100.0m USD
EBITDA TTM = 100.8m USD
Long Term Debt = 5.59m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.51m USD (from shortTermDebt, last fiscal year)
Debt = 5.59m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -246.8m USD (from netDebt column, last quarter)
Enterprise Value = 377.2m USD (903.9m + Debt 5.59m - CCE 532.3m)
Interest Coverage Ratio = -8.93 (Ebit TTM 100.0m / Interest Expense TTM -11.2m)
FCF Yield = 25.77% (FCF TTM 97.2m / Enterprise Value 377.2m)
FCF Margin = 26.66% (FCF TTM 97.2m / Revenue TTM 364.5m)
Net Margin = 41.04% (Net Income TTM 149.6m / Revenue TTM 364.5m)
Gross Margin = 78.82% ((Revenue TTM 364.5m - Cost of Revenue TTM 77.2m) / Revenue TTM)
Gross Margin QoQ = 77.61% (prev 79.97%)
Tobins Q-Ratio = 0.51 (Enterprise Value 377.2m / Total Assets 734.6m)
Interest Expense / Debt = 58.81% (Interest Expense 3.29m / Debt 5.59m)
Taxrate = 14.66% (3.75m / 25.6m)
NOPAT = 85.4m (EBIT 100.0m * (1 - 14.66%))
Current Ratio = 9.75 (Total Current Assets 666.3m / Total Current Liabilities 68.3m)
Debt / Equity = 0.01 (Debt 5.59m / totalStockholderEquity, last quarter 653.4m)
Debt / EBITDA = -2.45 (Net Debt -246.8m / EBITDA 100.8m)
Debt / FCF = -2.54 (Net Debt -246.8m / FCF TTM 97.2m)
Total Stockholder Equity = 651.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 20.36% (Net Income 149.6m / Total Assets 734.6m)
RoE = 22.97% (Net Income TTM 149.6m / Total Stockholder Equity 651.3m)
RoCE = 15.23% (EBIT 100.0m / Capital Employed (Equity 651.3m + L.T.Debt 5.59m))
RoIC = 12.13% (NOPAT 85.4m / Invested Capital 703.8m)
WACC = 9.63% (E(903.9m)/V(909.5m) * Re(9.69%) + (debt cost/tax rate unavailable))
Discount Rate = 9.69% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -13.74%
[DCF Debug] Terminal Value 71.75% ; FCFE base≈122.5m ; Y1≈117.5m ; Y5≈114.7m
Fair Price DCF = 24.52 (DCF Value 1.55b / Shares Outstanding 63.2m; 5y FCF grow -5.45% → 3.0% )
EPS Correlation: -35.36 | EPS CAGR: -23.01% | SUE: 0.12 | # QB: 0
Revenue Correlation: -60.43 | Revenue CAGR: -12.28% | SUE: 0.34 | # QB: 0

Additional Sources for INMD Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle